The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Clofazimine (Brand name: Lamprene®)
- Manufactured by
Novartis Pharmaceutical Corporation
FDA-approved indication: Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.
National Library of Medicine Drug Information Portal
Thalidomide (Brand name: Thalomid)
- Manufactured by
Celgene Corporation
FDA-approved indication: Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.
National Library of Medicine Drug Information PortalMedline Plus Health Information